Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 301–400 of 1,000
Thillai, K., Lam, H., Sarker, D., & Wells, C. M. (2016) · Oncotarget · doi:10.18632/oncotarget.13309 · Cited by 38
Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells
Chung, S. T. M., Geerts, D., Roseman, K., Renaud, A., & Connelly, L. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0606-y · Cited by 40
Muta, Y., Matsuda, M., & Imajo, M. (2019) · Cancers · doi:10.3390/cancers11040513 · Cited by 37
Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways
Adam, C., Fusi, L., Weiss, N., Goller, S. G., Meder, K., Frings, V. G., Kneitz, H., Goebeler, M., Houben, R., Schrama, D., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.972 · Cited by 40
Genetic alterations and their therapeutic implications in epithelial ovarian cancer
Lapke, N., Chen, C., Chang, T., Chao, A., Lu, Y., Lai, C., Tan, K. T., Chen, H., Lu, H., & Chen, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08233-5 · Cited by 43
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers
Hofmann, M.-C. C., Kunnimalaiyaan, M., Wang, J. R., Busaidy, N. L., Sherman, S. I., Lai, S. Y., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0129 · Cited by 53
Zhong, X., Lee, H., & Surh, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.171 · Cited by 39
Mahon, R. N., & Hafner, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ621 · Cited by 40
Huth, H. W., Albarnaz, J. D., Torres, A. A., Bonjardim, C. A., & Ropert, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.05.009 · Cited by 37
Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma
Zhao, Y., Zhang, B., Yu, L., Sun, J., Zhang, Y., Yang, S., & Zhang, X. (2016) · Tumor Biology · doi:10.1007/s13277-016-5212-x · Cited by 37
XTalkDB: a database of signaling pathway crosstalk
Sam, S. A., Teel, J., Tegge, A. N., Bharadwaj, A., & Murali, T. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1037 · Cited by 39
Liao, T.-J., Jang, H., Nussinov, R., & Fushman, D. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10710 · Cited by 36
Tubita, A., Lombardi, Z., Tusa, I., Lazzeretti, A., Sgrignani, G., Papini, D., Menconi, A., Gagliardi, S., Lulli, M., Sbarba, P. D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0993 · Cited by 51
Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Zhang, D., Zhang, G., Hu, Z., Wu, L. W., Feng, Y., He, S., Zhang, Y., Hu, Z., Yang, L., Tian, T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1768 · Cited by 39
Talbert, E. E., Yang, J. J., Mace, T. A., Farren, M. R., Farris, A. B., Young, G. S., Elnaggar, O., Che, Z., Timmers, C. D., Rajasekera, P. V., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0337 · Cited by 36
Serasinghe, M. N., Gelles, J. D., Li, K., Zhao, L. M., Abbate, F., Syku, M., Mohammed, J. N., Badal, B., Rangel, C. A., Hoehn, K. L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0044-1 · Cited by 41
Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.016 · Cited by 36
Regulation of large and small G proteins by ubiquitination
Dohlman, H. G., & Campbell, S. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.011068 · Cited by 40
Modulating MGMT expression through interfering with cell signaling pathways
Bai, P., Fan, T., Wang, X., Zhao, L., Zhong, R., & Sun, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115726 · Cited by 39
Samson, S. C., Elliott, A., Mueller, B., Kim, Y., Carney, K. R., Bergman, J. P., Blenis, J., & Mendoza, M. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007431 · Cited by 32
S100A12 is a promising biomarker in papillary thyroid cancer
Wang, X., Sun, Z., Tian, W., Piao, C., Xie, X., Zang, J., Peng, S., Yu, X., & Wang, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-58534-1 · Cited by 35
Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
Qian, L. M., Chen, K., Wang, C., Chen, Z., Meng, Z., & Wang, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2604 · Cited by 36
Tian, W., Ji, X., Xue, J., Gao, Y., Zhu, X., & Xiao, G. (2020) · Food & Function · doi:10.1039/d0fo02107e · Cited by 37
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 37
Bersani, F., Lingua, M. F., Morena, D., Foglizzo, V., Miretti, S., Lanzetti, L., Carrà, G., Morotti, A., Ala, U., Provero, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0709 · Cited by 37
Lulli, D., Carbone, M., & Pastore, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102227 · Cited by 34
Wnt signaling in cell adhesion, development, and colon cancer
Tejeda‐Muñoz, N., & Mei, K. (2024) · IUBMB Life · doi:10.1002/iub.2806 · Cited by 35
Qiu, R., Ma, H., Wang, L., Qin, J., Tian, M., & Zhang, W. (2024) · Current Genomics · doi:10.2174/0113892029298721240627095839 · Cited by 37
Li, G., Li, D., Zhai, W., Liu, C., Chen, M., Xu, Q., & Huang, Y. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118494 · Cited by 41
Kodama, T., Bard-Chapeau, E. A., Newberg, J. Y., Kodama, M., Rangel, R., Yoshihara, K., Ward, J. M., Jenkins, N. A., & Copeland, N. G. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.040 · Cited by 34
Leoncini, P. P., Bertaina, A., Papaioannou, D., Flotho, C., Masetti, R., Bresolin, S., Menna, G., Santoro, N., Zecca, M., Basso, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10577 · Cited by 34
Kalimutho, M., Bain, A. L., Mukherjee, B., Nag, P., Nanayakkara, D. M., Harten, S. K., Harris, J. L., Subramanian, G. N., Sinha, D., Shirasawa, S., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12040 · Cited by 38
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer
Tang, Q., Wu, L., Xu, M., Yan, D., Shao, J., & Yan, S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.07.2322 · Cited by 37
Chen, C., Zhang, M., & Zhang, Y. (2020) · Cell Transplantation · doi:10.1177/0963689720961070 · Cited by 33
A Sos proteomimetic as a pan-Ras inhibitor
Hong, S. H., Yoo, D. Y., Conway, L. P., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101027118 · Cited by 36
Lebedev, T. D., Khabusheva, E., Mareeva, S. R., Ivanenko, K. A., Morozov, A. V., Spirin, P., Рубцов, П. М., Snezhkina, A. V., Kudryavtseva, A. V., Sorokin, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102226 · Cited by 35
Non-Coding RNA Related to MAPK Signaling Pathway in Liver Cancer
Wang, Q., Feng, J., & Tang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911908 · Cited by 39
Gaudio, E., Tarantelli, C., Kwee, I., Barassi, C., Bernasconi, E., Rinaldi, A., Ponzoni, M., Cascione, L., Targa, A., Stathis, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw131 · Cited by 34
Memmel, S., Sisario, D., Zoeller, C., Fiedler, V., Katzer, A., Heiden, R., Becker, N., Eing, L., Ferreira, F. L. R., Zimmermann, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16847 · Cited by 39
Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth
Gupta, R., Forloni, M., Bisserier, M., Dogra, S. K., Yang, Q., & Wajapeyee, N. (2016) · eLife · doi:10.7554/elife.16432 · Cited by 34
Siyo, V., Schäfer, G., Hunter, R., Grafov, A., Grafov, A., Nieger, M., Katz, A. A., Parker, M. I., & Kaschula, C. H. (2017) · Molecules · doi:10.3390/molecules22060892 · Cited by 33
In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma
Ren, L., Li, Z., Wang, Y., Teng, Y., Sun, H., Xing, B., Yang, X. Y., Jiang, Y., & He, F. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000421 · Cited by 31
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
Morales, M. L., Arenas, A., Ortiz-Ruiz, A., Leivas, A., Rapado, I., Rodríguez-García, A., Castro, N., Zagorac, I., Quintela-Fandiño, M., Goméz-López, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54901-9 · Cited by 34
Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32
Ni, Y., Liu, J., Zeng, L., Yang, Y., Liu, L., Yao, M., Chai, L., Zhang, L., Li, Y., Zhang, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1109822 · Cited by 39
Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
Saei, A., & Eichhorn, P. J. A. (2019) · Cancers · doi:10.3390/cancers11081176 · Cited by 35
Daley, B. R., Vieira, H. M., Rao, C., Hughes, J. M., Beckley, Z., Huisman, D. H., Chatterjee, D., Sealover, N. E., Cox, K., Askew, J. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313137120 · Cited by 32
Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
Takahashi, M., Li, Y., Dillon, T. J., Kariya, Y., & Stork, P. A. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00132-17 · Cited by 27
Liu, C., Chu, P., Huang, C., Chen, J., Yang, H., Wang, W., Lau, K.-Y., Lee, C., Lan, T.-Y., Huang, T., et al. (2019) · Cancers · doi:10.3390/cancers11010105 · Cited by 33
Kim, J., Kim, B., Kim, S., Yang, C. E., Song, S. Y., Lee, W. J., & Lee, J. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102546 · Cited by 33
Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 36
Trinidad, A. G., Whalley, N., Rowlinson, R. A., Delpuech, O., Dudley, P., Rooney, C., & Critchlow, S. E. (2017) · Oncogene · doi:10.1038/onc.2017.224 · Cited by 33
Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 30
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
Thillai, K., Ross, P., & Sarker, D. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i2.173 · Cited by 32
Insulin specifically regulates expression of liver and muscle phosphofructokinase isoforms
Ausina, P., SILVA, D. N. N. D., Majerowicz, D., Zancan, P., & Sola‐Penna, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.033 · Cited by 30
Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma
Molina, M. L., García‐Bernal, D., Martínez, S., & Valdor, R. (2019) · Cancers · doi:10.3390/cancers12010102 · Cited by 31
Sorafenib‐Loaded Long‐Circulating Nanoliposomes for Liver Cancer Therapy
Ye, H., Zhou, L., Jin, H., Chen, Y., Cheng, D., & Jiang, Y. (2020) · BioMed Research International · doi:10.1155/2020/1351046 · Cited by 35
The Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Ney, G. M., McKay, L. M., Koschmann, C. J., Mody, R. J., & Li, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0916 · Cited by 36
Sun, R., Zheng, Z., Wang, L., Cheng, S., Shi, Q., Qu, B., Fu, D., Lebœuf, C., Zhao, Y. F., Ye, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12834 · Cited by 35
PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK
Cho, E., Lou, H. J., Kuruvilla, L., Calderwood, D., & Turk, B. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108928 · Cited by 30
Luo, G., Wang, B., Hou, Q., & Wu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01729 · Cited by 30
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles
Eisenhardt, A. E., Sprenger, A., Röring, M., Herr, R., Weinberg, F., Köhler, M., Braun, S. L., Orth, J. H. C., Diedrich, B., Lanner, U., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8427 · Cited by 35
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma
Boregowda, R. K., Medina, D. J., Markert, E. K., Bryan, M. A., Chen, W., Chen, S., Rabkin, A., Vido, M. J., Gunderson, S., Chekmareva, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8822 · Cited by 32
Kahen, E., Brohl, A. S., Yu, D. X., Welch, D. L., Cubitt, C. L., Lee, J. K., Chen, Y., Yoder, S., Teer, J. K., Zhang, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25181 · Cited by 30
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
Peng, U., Wang, Z., Pei, S., Ou, Y., Hu, P., Liu, W., & Song, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5340 · Cited by 31
Huth, H. W., Santos, D. M., Gravina, H. D., Resende, J. M., Goes, A. M., de Lima, M. E., & Ropert, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5452 · Cited by 32
Ning, C., Liang, M., Liu, S., Wang, G., Edwards, H. J., Xia, Y., Polin, L., Dyson, G. E., Taub, J. W., Mohammad, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17869 · Cited by 33
Molecular mechanisms of anticancer activities of polyphyllin VII
Ahmad, B., Rehman, S. U., Azizullah, A., Khan, M. F., Din, S. R. U., Ahmad, M., Ali, A., Tahir, N., Azam, N., Gamallat, Y., et al. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13818 · Cited by 31
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
Zhang, H., Zhang, L., Yang, C.-C., Li, J., Tian, X.-Y., Li, D., Cui, J., & Cai, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245876 · Cited by 29
Ahmad, B., Gamallat, Y., Khan, M. F., Din, S. R. U., Israr, M., Ahmad, M., Tahir, N., Azam, N., Rahman, K. U., Wang, X., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s287354 · Cited by 30
Hikita, T., Uehara, R., Itoh, R. E., Mitani, F., Miyata, M., Yoshida, T., Yamaguchi, R., & Oneyama, C. (2022) · Cancer Science · doi:10.1111/cas.15288 · Cited by 35
Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases
Pikoulis, E. A., Margonis, G. A., Andreatos, N., Sasaki, K., Angelou, A., Polychronidis, G., Pikouli, A., Riza, E., Pawlik, T. M., & Antoniou, E. (2016) · Anticancer Research · doi:10.21873/anticanres.11040 · Cited by 33
Kharbili, M. E., Robert, C., Witkowski, T., Danty, E., Barbollat‐Boutrand, L., Masse, I., Gadot, N., de la Fouchardière, A., McDonald, P. C., Dedhar, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15084 · Cited by 34
Gampa, G., Kim, M., Cook-Rostie, N., Laramy, J. K., Sarkaria, J. N., Paradiso, L. J., DePalatis, L., & Elmquist, W. F. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079194 · Cited by 30
Babiker, H. M., Byron, S. A., Hendricks, W. P. D., Elmquist, W. F., Gampa, G., Vondrak, J., Aldrich, J., Cuyugan, L., Adkins, J. R., DeLuca, V. J., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0668-8 · Cited by 28
Zhang, F., & Cao, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4655 · Cited by 30
Xu, H., Zhao, H., & Yu, J. (2018) · Europe PMC (PubMed Central) · Cited by 28
Karcioglu, A. S., Iwata, A. J., Pusztaszeri, M. P., Ahmed, A. H. A., & Randolph, G. W. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22519 · Cited by 28
Tai, W., Wong, W., Lee, M. M., Chan, B., Lu, C. C., & Hsiao, W. L. W. (2016) · PROTEOMICS · doi:10.1002/pmic.201500293 · Cited by 28
Targeting ERK signaling pathway by polyphenols as novel therapeutic strategy for neurodegeneration
Farzaei, M. H., Tewari, D., Momtaz, S., Argüelles, S., & Nabavi, S. M. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.07.010 · Cited by 29
Optogenetic technologies in translational cancer research
Malogolovkin, A. S., Egorov, A. D., Karabelsky, A. V., Ivanov, R. A., & Verkhusha, V. V. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.108005 · Cited by 27
Recent advances in antitumor Pt(IV) complexes: Dual targeting and chemoimmunotherapy
Spector, D. V., Zharova, A., Bykusov, V., Karetnikov, G. L., Beloglazkina, E. K., & Krasnovskaya, O. O. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216808 · Cited by 29
Gao, Y., Luo, L., Li, T., Ma, L., Yuan, M., Sun, W., Cheng, H., Niu, L., Du, Z., Quan, Z., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4774 · Cited by 33
Zeng, J., Wu, Y., Zhuang, S., Qin, L., Hua, S., Mungur, R., Pan, J., Zhu, Y., & Zhan, R. (2019) · Oncology Reports · doi:10.3892/or.2019.7260 · Cited by 29
SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis
Liu, R., Shuai, Y., Luo, J., & Zhang, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01035 · Cited by 27
Bandyopadhayaya, S., Akimov, M., Verma, R., Sharma, A., Sharma, D., Kundu, G. C., Gretskaya, N. M., Безуглов, В. В., & Mandal, C. C. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22693 · Cited by 29
Cheng, J., Feng, X., Li, Z., Zhou, F., Yang, J., & Zhao, Y. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00361a · Cited by 30
Tubita, A., Tusa, I., & Rovida, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647311 · Cited by 31
mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK
Wu, H., He, D. N., Biswas, S., Shafiquzzaman, M., Zhou, X., Charron, J., Wang, Y., Nayak, B. K., Habib, S. L., Liu, H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3979 · Cited by 30
Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective
Kanakis, M. G., Petrou, P., Lourida, P., & Georgalas, I. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.013 · Cited by 31
Stephens, E. A., Ludwicki, M. B., Meksiriporn, B., Li, M., Ye, T., Monticello, C., Forsythe, K. J., Kummer, L., Zhou, P., Plückthun, A., et al. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00357 · Cited by 27
Vemurafenib/dabrafenib and trametinib
Rißmann, R., Hessel, M. H. M., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12651 · Cited by 27
Molecular genetic and immunotherapeutic targets in metastatic melanoma
Melis, C., Rogiers, A., Bechter, O. E., & van den Oord, J. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2113-3 · Cited by 31
Tao, S., Huang, J., Wei, Z., Li, Z., & Guo, S. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000152 · Cited by 29
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
Kwon, J. J., & Hahn, W. C. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00627-20 · Cited by 28
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
Portelinha, A., Thompson, S. K., Smith, R. A., Ferreira, M. D. S., Asgari, Z., Knežević, A., Seshan, V., de Stanchina, E., Gupta, S., Denis, L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100350 · Cited by 37
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.